Equibles does not estimate personal net worth.
Get an email with a short summary when BridgeBio Oncology Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get BBOT alertsEdan Mellick is recorded as COO at BridgeBio Oncology Therapeutics, Inc. (BBOT). Edan Mellick has spoken on 1 investor event across 1 company, most recently for BridgeBio Oncology Therapeutics, Inc. on September 10, 2026. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Eli Wallace (CEO and Board Member), Pedro Beltran, Ph.D. (CEO and Board Member), Pedro J. Beltran, Ph.D. (CEO and Board Member) and 7 others.
“I imagine, you know, monotherapeutically you know the real effect of it this value is kind of seen in the combination regimen i imagine right so i guess should we expect much from an efficacy standpoint as from its monotherapy monotherapeutic profile yeah i think i mean inhibitors of the pi3k alpha pathway um you know…”
Biotechnology · Healthcare
COO
